Caplacizumab interferes with vWF, which is crucial for hemostasis, potentially leading to mucocutaneous bleeding similar to that in patients with von Willebrand disease [3]. Bleeding is generally mucocutaneous and manageable; dose interruption may be required for invasive procedures. The gene discussed is VWF; the disease is platelet-type von Willebrand disease.